What is Apicore US?
Headquartered in Somerset, New Jersey, Apicore US operates as a sophisticated developer and manufacturer of specialty Active Pharmaceutical Ingredients (APIs). The company maintains a diverse portfolio, including over 100 distinct APIs and a significant number of Abbreviated New Drug Applications (ANDAs). With two FDA-approved facilities—one in the United States and another in Vadodara, Gujarat—the firm possesses the technical agility to scale production from gram-level laboratory quantities to industrial-scale volumes of up to 60 metric tons annually. Their market position is defined by a focus on difficult-to-synthesize, high-value niche APIs, serving both generic and branded pharmaceutical entities globally.
How much funding has Apicore US raised?
Apicore US has raised a total of $16.7M across 3 funding rounds:
Unspecified
$6.8M
Unspecified
$9.2M
Private Equity
$720K
Unspecified (2014): $6.8M with participation from Undisclosed
Unspecified (2014): $9.2M led by Undisclosed
Private Equity (2016): $720K, investors not publicly disclosed
Key Investors in Apicore US
Undisclosed Investors
Undisclosed Investors
Undisclosed Investors
What's next for Apicore US?
Looking ahead, the recent capital injection is expected to accelerate Apicore US's strategic initiatives in process chemistry and regulatory expansion. With a proven track record of submitting Drug Master Files to the FDA, the company is well-positioned to capitalize on the growing demand for high-quality, compliant pharmaceutical ingredients. Future growth will likely center on expanding its commercial footprint and deepening its research capabilities to address the next generation of complex therapeutic molecules. By optimizing its dual-facility manufacturing model, Apicore US aims to further solidify its competitive advantage in the high-barrier-to-entry API market, ensuring long-term value creation for its stakeholders and partners.
See full Apicore US company page
